Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern
Madalina E. Carter-Timofte(Aarhus University Hospital), David Olagnier(Aarhus University), Jean‐Simon Diallo(University of Ottawa), Taha Azad(Université de Sherbrooke), Daniele Di Carlo(Istituto Pasteur), Luc A. Sabourin(Ottawa Hospital), Renée M. van der Sluis(Aarhus University), Anne Louise Hansen(Aarhus University), Christian K. Holm(Aarhus University), John Hiscott(Istituto Pasteur), John C. Bell(Ottawa Hospital), Kathy Fu(University of Ottawa), Naziia Kurmasheva(Aarhus University), Jean R. Séguin(Research Unit on Children's Psychosocial Maladjustment), Julien van Grevenynghe(Institut National de la Recherche Scientifique), Enrico Palermo(Istituto Pasteur), Fanghui Ren(Aarhus University), Léna Cassin(Aarhus University), Marceline Côté(University of Ottawa), Martin R. Jakobsen(Aarhus University), Glib Maznyi(Ottawa Hospital), Geneviève Laroche(University of Ottawa), Ragunath Singaravelu(Ottawa Hospital), Tommy Alain(University of Ottawa), Søren R. Paludan(Aarhus University), Manja Idorn(Aarhus University), Zaid Taha(University of Ottawa), Rozanne Arulanandam(Ottawa Hospital), David H. Jacobs(University of Ottawa), Demi van der Horst(Aarhus University)
Cited by 26
Related Papers
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-κB Signaling after Nuclear DNA Damage
|Molecular Cell|2018|663
Hostile takeovers: viral appropriation of the NF-kB pathway
|Journal of Clinical Investigation|2001|606